Stromal PDGFR-beta expression is a prognostic factor in high-grade serous ovarian cancer patients but is it also predictive for response to antiangiogenic treatment?

However, the same trend could be observed in patients treated with platinum-based chemotherapy alone (n = 72) even though the results did not reach statistical significance in this smaller subgroup (Fig. 1 F; p = 0.343; p = 0.343; median overall survival of 57 patients with weak/moderate PDGFR-beta: 50 months, 95% CI 22.3–77.7 months; median overall survival of 15 patients with strong PDGFR-beta: 32 months, 95% CI 13.6–50.4 months).

also in 111,027 other papers